| Ms Lisa J Lieber-summers, LSCSW | |
|
8000 Lee Blvd, Leawood, KS 66206-1217 | |
| (913) 381-4992 | |
| Not Available |
| Full Name | Ms Lisa J Lieber-summers |
|---|---|
| Gender | Female |
| Speciality | Counselor - Mental Health |
| Location | 8000 Lee Blvd, Leawood, Kansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124399175 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YM0800X | Counselor - Mental Health | 2490 (Kansas) | Primary |
| 101YM0800X | Counselor - Mental Health | 2012002892 (Missouri) | Secondary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Lisa J Lieber-summers, LSCSW 6248 W 155th St, Overland Park, KS 66223-3593 Ph: (913) 239-8410 | Ms Lisa J Lieber-summers, LSCSW 8000 Lee Blvd, Leawood, KS 66206-1217 Ph: (913) 381-4992 |
News Archive
Very low doses of a drug used to treat certain types of cancer protect the insulin-producing cells in the pancreas and prevent the development of diabetes mellitus type 1 in mice. The medicine works by lowering the level of so-called sterile inflammation. The findings have been made by researchers from the University of Copenhagen, the Technical University of Denmark and the University of Southern Denmark working with researchers in Belgium, Italy, Canada, Netherlands and the USA.
Funding cuts and austerity measures are damaging young people's access to mental health services, with potentially long-term consequences for their mental wellbeing, say researchers at the University of Cambridge.
EntreMed, Inc. today announced the initiation of a multi-center Phase 2 study with its lead oncology product candidate, ENMD-2076, in patients with platinum resistant ovarian cancer. The study will be conducted at up to six sites in the United States and Canada. In addition, EntreMed received a No Objection Letter (NOL) from the Therapeutic Products Directorate of Health Canada on its Clinical Trial Application to conduct the Phase 2 clinical trial in ovarian cancer patients.
Researchers from the 'Angiogenesis signaling pathways' research group of the Institute of Biomedical Investigation of Bellvitge, led by Dr. Mariona Graupera, have unveiled the potential therapeutic benefit of a selective inhibitior of the PI3-kinase (PI3K) protein in pancreatic neuroendocrine tumors (PanNETs).
› Verified 3 days ago
Morgan Milligan, Counselor Medicare: Not Enrolled in Medicare Practice Location: 4901 W 136th St, Leawood, KS 66224 Phone: 913-488-2012 | |
Nicole Schafer, Counselor Medicare: Not Enrolled in Medicare Practice Location: 6700 W 121st St Ste 102, Leawood, KS 66209 Phone: 636-323-9098 | |
Mary Ann Altenbernd, LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 8900 State Line Rd, Suite435, Leawood, KS 66206 Phone: 913-907-7911 Fax: 913-221-0152 | |
Dr. Elise Marie Dicarlo, Counselor Medicare: Not Enrolled in Medicare Practice Location: 13104 Alhambra St, Leawood, KS 66209 Phone: 913-375-4900 | |
Jason Thomas Miller, MSW, LCSW Counselor Medicare: Accepting Medicare Assignments Practice Location: 5401 College Blvd, Suite 106, Leawood, KS 66211 Phone: 913-636-8566 Fax: 888-515-3097 | |
Andrea Lynn Linnebach, Counselor Medicare: Not Enrolled in Medicare Practice Location: 6400 W 110th St Ste 203, Leawood, KS 66211 Phone: 913-667-0829 |